medigraphic.com
ISSN 0185-3252 (Impreso)
Revista de la Asociación Médica del Centro Médico ABC

2001, Número 4

<< Anterior Siguiente >>

An Med Asoc Med Hosp ABC 2001; 46 (4)


Utilización de cisaprida y su relación con arritmia cardiaca
Estado actual en la literatura médica

Flores AA, Rodríguez TG, Valles RR, Ramírez ES

Idioma: Español
Referencias bibliográficas: 104
Paginas: 183-192
Archivo PDF: 99.01 Kb.


RESUMEN

El monohidrato de cisaprida es el procinético más utilizado para el tratamiento de desórdenes sintomáticos de la motilidad intestinal; ha sido utilizado tanto en niños como en adultos; se encuentra disponible en presentación como suspensión pediátrica en un gran número de países incluyendo México desde 1984. Se calcula que ha sido prescrito en más de 140 millones de pacientes. Los aspectos con relación a su farmacocinética y farmacodinámica han sido reevaluados desde los reportes de su utilización y su asociación con alargamiento del segmento electrocardiográfico QT, arritmia ventricular y muerte. Hasta diciembre de 1999 se habían reportado 80 muertes asociadas con su utilización. Janssen decidió limitar su producción en los Estados Unidos, dejándolo en disponibilidad sólo para protocolos de investigación. Con estos antecedentes se han realizado análisis retrospectivos, estudios prospectivos en poblaciones de distintas edades, con búsqueda y hallazgo de factores de riesgo hasta en 85% de los pacientes que han presentado arritmias ventriculares. La finalidad de este documento es revisar los aspectos farmacológicos de la cisaprida, comentar los factores identificables asociados con arritmia ventricular, y realizar una revisión de los aspectos seguridad y eficacia de la cisaprida, así como establecer factores de riesgo para presentar arritmia ventricular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mc Callum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride: A preliminary review of its pharmacodynamic and pharmokinetic properties and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652-681.

  2. Rendic S, Di Carlo F. Human cytochrome P 450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29: 413-580.

  3. Watkins PB. Non invasive test of CYP3A enzymes. Pharmacolgenetics 1994; 4: 171-184.

  4. Ritschel WA, Kearns GL. Drug biotransformation. In: Handbook of basic pharmacokinetics. 5th ed. Washington, DC: American Pharmaceutical Association, 1998: 138.

  5. Horsmans Y. Major cytochrome P 450 families: Implications in health and liver diseases. Acta Gastroenterol Belg 1997; 60: 2-10.

  6. Vandenplas Y, Lifshitz JZ, Orenstein SR et al. Nutritional management of regurgitations in infants. J Am Coll Nutr 1998; 17: 308-316.

  7. Lacroix D, Sonnie M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in human liver: Evidence that the shift between CYP3A4 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-3421.

  8. Cresteil T. Determinants of the ontogenetic development of the human P450 sistem. Exp Toxic Pathol 1996; 48: 341.

  9. Leeder JS, Kearns GL. Pharmacokinetics in pediatrics: Implications for practice. Pediatr Clin North Am 1997; 44: 55-77.

  10. Boehm G, Teichmann B, Krumbiegel P. Hepatic biotransformation capacity in low birth-weight infants as measured with the (15N) methacetin urine test: Influences of gestational age, postnatal age, and intrauterine growth retardation. Biol Neonate 1995; 68: 19-25.

  11. Meuldermans W, Van Peer A, Hendrickx J et al. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988; 16: 403-409.

  12. Preechagoon Y, Charles B, Piotrovsky V, Donovan T, Van Peer A. Population pharmacokinetics of enterally administered Cisapride in young infants with gastroesophageal reflux disease. Br J Clin Pharmacol 1999; submitted.

  13. Kneepkeris CMF, Vn Weissenbruch MM, Kulik W et al. Effect of cisapride on gastric emptying in preterm infants (abstract). Presented at the 5th Join meeting of ESPGHAN/NASPGN, Toulouse, France, May 1998.

  14. Van’t Klooster G, Piotrovsky V, Van Peer A. Cisapride pharmacokinetics in paediatrics: A review of the data available until June 1998. N 135638, August 1998, Janssen Research Foundation. Beerse, Belgium.

  15. Castro HE, Ferrero GB, Cortina LS, Salces C, Lima M. Efectividad de cisaprida en el tratamiento del reflujo gastroesofágico en niños. Valoración de un estudio a doble ciego. An Espagnol Ped 1994; 40: 5-8.

  16. Cucchiara S, Staino A, Boccieri A, De Sefano M, Capozzi C, Manzi G et al. Effects of cisapride on parameters of oesophageal motility and on the prolongs intraoesophageal pH test in infants with gastroesophageal reflux disease. Gut 1990; 31: 21-25.

  17. Scott RB, Ferreira C, Smith L, Jones AB, Machida H, Louhose MJ et al. A double-blind, randomized placebo-controlled study of cisapride in paediatric reflux. Gut 1996; 39: (suppl 3): A35.

  18. Vandenplas Y, De Roy C, Sacre L. Cisapride decreases prolonged episodes of reflux in infants. J Pediat Gastroenterol Nutr 1991; 12: 44-47.

  19. Van Eygen M, Van Ravensteyn H. Effect of cisapride on excessive regurgitation in infants. Clin Ther 1989; 11: 669-677.

  20. Cucchiara S, Staiano A, Capzzi C, Di Lorenzo C, Bocceieri A, Auricchio S. Cisapride for gastroesophageal reflux and peptic oesophagitis. Arch Dis Child 1987; 62: 454-457.

  21. Saye Z, Forget P, Geubelle F. Effect of cisapride on gastroesophageal reflux in children with chronic bronchopulmonary disease. Pediat Pulmol 1987; 3: 8-12.

  22. Bravo Matus CA, Flores RM. Estudio comparativo entre cisaprida y metroclopamida en neonatos con reflujo gastroesofágico. Invest Med Intern 1995; 22: 3-7.

  23. Evans DF, Ledingham SJ, Kapilla L. The effect of medical therapy on gastroesophageal reflux disease in children. World Congress on Gastroenerology. Sydney, Australia. August 26-31 1990 (abstract).

  24. González Galicia JAG, Galindo SJ, Morán ES. Valoración clínica y endoscópica de la eficacia de cisapride en comparación con metroclopamida en el reflujo gastroesofágico en niños. Invest Med Intern 1992; 19: 10-15.

  25. Greally P, Hamton FJ, Mc Fadyen UM, Simpson H. Gaviscon and Carobel compared with cisapride in gastroesophageal reflux. Arch Dis Child 1992; 67: 618-621.

  26. Mundo F, Feregrino H, Fernández J, Teramoto O, Abad P, Rodríguez C. Clinical evaluation of gastro-oesophageal reflux in children. A double blind study of cisapride vs metroclopamide. Am J Gastroenterol 1990; 85: A29.

  27. Vanderplas Y, Deneyer M, Verlinden M, Asrts T, Sacre L. Gastroesophageal reflux incidence and respiratory dysfunction during sleep in infants: Treatment with cisapride. J Pediatr Gastroenterol Nutr 1989; 8: 31-36.

  28. Smith HL, Handy DJ, Weller PH, Booth IW. Cisapride and cystic fibrosis. Lancet 1989; 1: 338.

  29. Rode H, Stunden RJ, Millar AJW, Cywes S. Oesophageal pH assessment of gastro-esophageal reflux in 18 patients and the effect of two prokinetic agents: Cisapride vs metroclopramide. J Pediatr Surg 1987; 22: 932-934.

  30. Daoud G, Stanzione C, Abraham A, López C, Henríquez S, Dahadah J, Puig M et al. Response to cisapride in children with respiratory symptoms and gastroesophageal reflux evaluated by prolonges intraesophageal pH monitoring. Second United European Gastroenterology Week. Barcelona, Spain. July 19-24 1993 (abstract).

  31. Dupont C, Chouraqui JP, Leluyer B, Oliver JP, Poujol A, Meyer M et al. Etude de l’efficacité et de la tolérance d cisapride dans la traitement du feflux gastro-oesophagien de l’enfant. Ann Pediatr (Paris) 1995: 515-525.

  32. Malfoot A, Vandenplas Y, Verlinden M, Piepsz A, Dab I. Gastroesopageal reflux and unexplained chronic respiratory disease in infants and children. Pediatr Pulm 1987; 3: 208-213.

  33. Saye Z, Forget P. Effect of cisapride on gastroesophageal pH monitoring in children with reflux-associated chronic bronchopulmonary disease. J Pediatr Gastroenterol Nutr 1989; 8: 327-332.

  34. Blecker U De ont MHB, Hauser B, Chouraqui TP, Gottrand F, Vandenplas Y. The role of “occult” gastroesophageal reflux in chronic pulmonary disease in children. Acta Gastroenterol Belg 1995; 58: 348-352.

  35. Vanderwinder JM, Van der Veken E, Dassonville, Lerminiauz C, Perimutter N, de laer M-H. Long-term relief after treatment with cisapride in case of idiopathic dyskinetic sandifer syndrome. Hepato-Gastroenterol 1989; 36: 278.

  36. Daoud G, González L, Medine M, Stanzione C, Abraham A, Puig M, Daoud N et al. Efficacy of cisapride in infants with apnea and gastroesophageal reflux evaluates by prolongs intraoesophageal pH monitoring. Second Unites European Gastroenerology Week. Barcelona, Spain. July 19-24, 1993 (abstract).

  37. Cohen NP, Booth IW, Parashar K, Corkey JJ. Successful management of idiopathic intestinal pseudo-obstruction with cisapride. J Pediatr Surg 1988; 23: 229-230.

  38. Coombs RC, Booth IW. Small intestinal motor activity response to cisapride in children with dysmotility syndromes. Gut 1989; 30: A 1473-1474.

  39. Di Lorenzo C, Reddy SN, Villanueva Meyer J, Mena I, Martin S, Hyman PE. Cisapride in children with chronic intestinal pseudo-obstruction. An acute double blind cross over placebo controlled trial. Gastroenterology 1991; 101: 1564-1570.

  40. Dunbar F, Rode H, Haus M. Medical intervention in children with chronic intestinal pseudo obstruction. International Symposium on Pharmacotherapy of Gastrointestinal Motor Disorders. Adelaide, Australia. September 2-4, 1990 (abstract).

  41. Hyman PE, Napolitana JA, Diego A, Patel S, Flores AF, Grill MB et al. Antroduodenal manometry in the evaluation of chronic functional gastrointestinal symptoms. Pediatrics 1990; 86: 39-44.

  42. Hyman Peer, McDiarmid SV, Napolitano J, Abrams CE, Tomamasa T. Antroduodenal motility in children with chronic intestinal pseudo obstruction. J Pediat 1988; 112: 899-905.

  43. Hyman PE, Di Lorenzo C, McAdams L, Flores AF, Tomomosa T, Garvey TQ. Predicting the clinical response to cisapride in children with chronic intestinal pseudo obstruction. Am J Gastroenterol 1993; 88: 832-836.

  44. Puntis JWL, Booth IW, Buick R. Cisapride in neonatal short gut. Lancet 1986; 1: 108-109.

  45. Reid B, Berseth CL. Using diagnostic duodenal manometro to predict success of two prokinetic agents in infants and children. 9th Biennial Meeting of the American Motility Society. Traverse City, Michigan, USA. September 29 October 1, 1996.

  46. Rode H, Dunbar F, Melis J, Cywes S. Medical intervention in clildren with chronic intestinal pseudo obstruction. In: Gastrointestinal Dysmotility: focus on cisapride. Heading RD, Wood JD (eds). New York: Raven Press, 1992: 345.

  47. Santer R, Leung YK. Improvement of intestinal morphology during cisapride therapy in pseudo obstruction. Gastroenterology 1989; 96: A439.

  48. Persic VN, Kos R, Kokai G. Acute intestinal pseudo obstruction (Ogilvie’s syndrome): The premonitory manifestations of ongoing rheumatoid arthritis. Arch Gastroenterol 1993; 12: 67-68.

  49. Mazloum BW, Barnes JB, Lee M. Cisapride as a successful treatment for acute intestinal pseudo obstruction. South Med J 1996; 89: 828-830.

  50. Murray RD, Ulysses B, Li K, Juhling McGlung H, Heitlinger L, Rehem D. Cisapride for intractable constipation in children: Observation from an open trial. J Pediatr Gastroenterol Nutr 1990; 11: 503-508.

  51. Nurko S, García JA, Guerro V. Use of cisapride in the treatment of children with chronic intractable constipation. Gastroenterology 1991; 100: A476.

  52. Valcke R, Van Hollebeke J, De Praeter N, Samuel K. Cisapride in the treatment of children and infants with dysxhezia and soiling. II Progresso Medico 1987; 43 (suppl 1) 1B1-1B5.

  53. Cadranel S. Effect of cisapride in chronically constipated children. 19th International Congress of Pediatrics. Paris France. July 22-28, 1989 (abstract).

  54. Staiano A, Cucchiara S, Andreotti MS, Minella R, Manzi G. Effect of cisapride on chronic idiopathic constipation in children. Dig Dis Sci 1991; 104: 733-736.

  55. Nurko S, García-Aranda JA, Worona LB, Zlochisty O. Cisapride for the treatment of constipation in children: A double-blind study. J Pediatr 2000; 136 (1): 35-40.

  56. Janssens G. Effect of cisapride in premature neonates at risk of pseudo obstruction. An open pilot study. Acta Antwerpiensia 1987; 4: 6-10.

  57. Melis K, Janssens G. Long-term use of cisapride in premature neonates. Acta Gasto Enterol Belg 1990: L1II: 372-375.

  58. Vanderplas Y, Scare L, Lobe H. The effect of cisapride on gastric stasis and gastroesophageal reflux in premature infants. In: Johnson AG, Lux G. Progress in the treatment of gastrointestinal motility disorders: The role of cisapride. Amsterdam. Excerpta Medica 1989: 158-163.

  59. Janssens G, Melis K, Vaerenberg M. Long-term use of cisapride in premature neonates of < 34 weeks gestacional age. J Pediatr Gastroenterol Nut 1990; 11: 420-422.

  60. Dutta U, Padhy AK, Ahuja V, Sharma MP. Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Trop Gastroenterol 1999; 20 (3): 116-119.

  61. De la Fuente PJA, De la fuente RI. Utilidad de un procinético cisaprida en el tratamiento abortivo de la migraña. Arch Neurocien (Mex) 1997; 2: 29-34.

  62. Vandenplas Y, Belli D, Benhamou P et al. A critical appraisal of current management practices for infant regurgitation: recommendations from a working party. Eur J Pediatri 1997; 156: 343-357.

  63. Gerald K McEvoy. Miscellaneous drugs. In: Gerald K McEvoy (eds). American Hospital Formulary Service Drug Information 96. The American Society of Health-System, Pharmacistis Inc; 1996; Ch 56: 40.

  64. Angeli L, Zorzi G, Rumi V, Nardocci N, Mennini T. Transient paroxysmal dystonia in an infant possibly induced by cisapride. Ital J NeuroI Sci 1996; 17: 157-159.

  65. Botarro G, Rotolo N, Spina M, Azzaro F, Galletta C, Romano D et al. Efficacy of cisapride in infants with gastroesophageal reflux disease. Ped Med Chir (Med Surg Ped) 1993; 15: 141-144.

  66. Boel M. Case report of a cisapride treatment in a child under chronic anti epileptic treatment. Data provided by Janssen Pharmaceutica.

  67. Galivanes A, Allit Ph, Devlieger H, Eggermont E. Cisapride induces cholestasis in the very low birth weight infant of postmentral age below 34 weeks. 19th Annual Meeting of the Velgian Society or Pediatrics. Brussels, Belgium. March 15-16, 1991.

  68. Ward RM, Lemons JA, Molteni RA. Cisapride: A survey of the frequency of use and adverse events in premature newborns. Pediatrics 1999; 103: 469-472.

  69. Hanson et al. (Editorial correspondence) Journal of Pediatrics 1997; 130: 164-165.

  70. Davignon A, Rautaharju P, Boiselle E, Soumis F, Mégélas M, Choquette A. Normal ECG standards for infants and children. Pediatric Cardiol 1980; 1: 123-131.

  71. Iturralde TP. Arritmias cardiacas 1997: 298-300.

  72. Karjalaine J, Ciitasalo M, Manttari M, Mannienen V. Relation between QT interval and heart rate from 40 to 120 beats/min in rest electrocardiograms of mean and a simple method to adjust QT interval values. J Am Coll Cardiol 1994; 23: 1547-153.

  73. Malik M. If Dr. Bazett had had a computer... Pacing. Clin Electrophysiol 1996; 19: 1635-1639.

  74. Kligfield P, Lax KG, Okin PM. QT interval-heart rate relation during exercise in normal men and women: Definition by linear regression analysis. J Am Coll Cardiol 1996; 28: 1547-1555.

  75. Sagie A, Larson MG, Golberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham study). Am J Cardiol 1992; 70: 797-801.

  76. Frunck Brentano C, Jaillon P. Rate corrected QT interval: Techniques and limitations. Am J Cardiol 1993; 72: 17B-22B.

  77. Rautahaju PM, Davingnon A, Soumis F, Boiselle E, Choquette A. Evolution of QRS-T relationship from birth to adolescence in frank-lead orthogonal electrocardiograms of 1492 normal children. Circulation 1979; 60: 196-204.

  78. Schwartz PJ, Montemerlo M, Facchini M, Salice P, Rosti D, Poggio G, Giorgetti R. The QT interval throughout the first 6 months of life: a prospective study. Circulation 1982; 66: 496-501.

  79. Ward OC. New familial cardiac syndrome in children. J Irish Med Assoc 1964; 54: 103-106.

  80. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J 1957; 54: 59-68.

  81. Villian E, Levy M, Kachaner J, Garson A. Prolonged QT interval in neonates. Begingn, transient, or prolonged risk of sudden death. Ani Heart J 1992; 124: 194-197.

  82. Wu JM, Wang JN, Lin CS, Lee WL, Wu MH. Long QT syndrome in children. Acta Paediatrica Sinica 1997; 38: 213-217.

  83. Bedford TA, Rowbotham DJ. Cisapride drug interaction of clinical significance. Drugs Safety 1996; 15: 167-175.

  84. Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 346: 122-123.

  85. Kivisto KT, Li1ja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66 (5): 448-453.

  86. Cheron G, Bernard F, Sallenave JR, Dupont C. Cisapride: absence of effects on cardiac rhythm. In: Heading RC, Wood JD (eds). Gastrointestinal dysmotility: focus on cisapride. New York: Raven Press, 1992: 327-328.

  87. Levine A, Fogelman R, Sirota L, Zangen Z, Shamir R, Dinari G. QT interval in children and infants receiving cisapride. Pediatrics 1998; 101: E9.

  88. Bernardini S, Semama DS, Huet F, Guyon JB. Effects of cisapride in QTc interval in neonates. Arch Dis Child 1997; 77: F241-F243.

  89. Mark B, Lewin MD, Bryant RM, Fenrinch AL, Grifka RG. Cisapride induced long QT interval. Pediatrics 1996; 128: 279-281.

  90. Bedu A. Cisapride high dosage and long QT interval (editorial correspondence). J Pediatrics 1997; 130: 164.

  91. Costalos C, Gounaris A, Varhalama E, Kokori F, Alexiou N, Katsarakis I. Effect of low-dose cisapride on gastric emptying and QTc interval in preterm infants. Acta Paediatr 2000; 89 (12): 1446-1448.

  92. Ramírez-Mayans J, Garrido-García LM, Huerta-Tecanhuey A, Gutierrez-Castrellon P, Cervantes-Bustamante R et al. Cisapride and QTc interval in children. Pediatrics 2000; 106 (5): 1028-1030.

  93. Benatar A, Feenstra A, Decraene T, Vandenplas Y. Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. Pediatrics 2000; 106 (6): E85.

  94. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B. Effects of cisapride on QT interval in children. J Pediatr 1998; 133: 51-56.

  95. Khoshoo V, Edell D, Clarke R. Effect of cisapride on the QT interval in infants with gastroesophageal reflux. Pediatrics 2000; 105 (2): E24.

  96. Moss, Adams. Heart disease in infants, children, and adolescents. 5th ed. Baltimore, Philadelphia: Williams and Wilkins, 1995: 1558-1564.

  97. Garson AJr. The science and practrice of pediatric cardiology. 2nd ed. Baltimore, Philadelphia: Williams and Wilkins, 1997: 774.

  98. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high dose cisapride. Arch Int Med 1995; 155: 765-768.

  99. Zsolt O, Mac Donald LL, Peteers MA et al. Erythromycin induced cardiac toxicity. Am J Cardiol 1995; 75: 859-861.

  100. Wysowsky DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 355: 290-291.

  101. Woodard JJ, Woolf A. Spectrum of toxicity see in cisapride poisoning. J Toxicology 1995; 33: 490.

  102. Gitler B, Berger LS, Buffa SD. Torsades de Pointes induced by erythromycin. Chest 1994; 105: 368-372.

  103. Walker AM, Szneke P, Bianchi L et al. The risk of serious cardiac arrhythmias among cisapride users in United Kingdom and Canada. Am J of Medicine 1999; 107: 356-362.

  104. Aman S, Wolfe SM. Cisapride and Torsade de Pointes. Lancet 1995; 345: 508.




2020     |     www.medigraphic.com